Iowa-based Harrisvaccines has
developed a vaccine for the H3N2 variant strain of swine flu and, using the
company's patented RNA Particle technology, can produce the vaccine within four
weeks without culturing the live virus.
Currently, the company has pending U.S. Department of Agriculture licensure for the technology.
“We have the ability to produce a swine vaccine for the H3N2 variant strain and
are prepared to work with federal officials to make it available should the
situation warrant,” said D.L. Harris, DVM, Ph.D., founder and president of Harrisvaccines. “Our patented RNA Particle platform allows for
rapid vaccine response to situations such as we saw in the 2009 pandemic H1N1
virus and today with the H3N2 variant strain that is crossing from pigs to
humans.
"Our technology is so advanced that the USDA’s Center for Veterinary
Biologics did not have a ‘box’ to put us in. Now that we have complied with all
the necessary testing and paperwork, we are still waiting to be regulated and
fully bring this technology to the market.”
No comments:
Post a Comment